Pfizer (PFE) Acquisitions (2009 - 2023)

Pfizer's (PFE) quarterly Acquisitions came in at $43.4 billion in Q4 2023, up 173520.0% quarter-over-quarter from $25.0 million in Q3 2023.

Analysis

Pfizer (PFE) Acquisitions (2009 - 2023) Analysis & Trends

Pfizer (PFE) has reported Acquisitions for 10 consecutive years, with $43.4 billion the latest figure, recorded in Q4 2023.

On a quarterly basis, Acquisitions changed N/A year-over-year to $43.4 billion in Q4 2023; TTM through Sep 2024 was $43.4 billion, a N/A change from a year earlier, with the FY2025 full-year figure at $6.9 billion, changed N/A from the prior year.
Acquisitions was $43.4 billion for Q4 2023 at Pfizer, up from $25.0 million in the prior quarter.
Over five years, Acquisitions peaked at $43.4 billion in Q4 2023 and troughed at $25.0 million in Q3 2023.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Acquisitions (Qtr)
1	Johnson & Johnson	641.14 Bn	620.38 Bn	17.26 Bn	-17.24 Bn
2	AbbVie	451.04 Bn	444.47 Bn	12.70 Bn	-
3	Merck	357.43 Bn	350.29 Bn	12.21 Bn	-
4	Novartis Ag	266.73 Bn	259.04 Bn	11.24 Bn	-23.00 Mn
5	Pfizer	157.52 Bn	145.82 Bn	10.94 Bn	-
6	Sanofi	52.14 Bn	44.76 Bn	10.79 Bn	-
7	Revolution Medicines	42.88 Bn	42.88 Bn	-	-
8	Incyte	24.70 Bn	20.16 Bn	1.57 Bn	-
9	United Therapeutics	21.47 Bn	18.80 Bn	683.80 Mn	-
10	Neurocrine Biosciences	15.82 Bn	15.43 Bn	935.80 Mn	-

Historic Data

Download Data